- From research to real-world impact: Lunit demonstrates
Lunit INSIGHT's clinical safety, effectiveness, and efficiency in
100 papers
SEOUL,
South Korea, May 20, 2024
/PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of
AI-powered solutions for cancer diagnostics and therapeutics, today
announced a groundbreaking achievement in the field of medical AI
research: the publication of 100 peer-reviewed papers in SCI
journals featuring its Lunit INSIGHT suite as of April 2024. This count strictly includes full
research articles, explicitly excluding abstracts and posters.
This collection of 100 papers showcases Lunit's pioneering
research, which has been featured in prestigious journals such as
The Lancet Digital Health, JAMA Oncology, and
Radiology. These studies not only bolster Lunit's standing
as a leader in AI-powered cancer diagnostics but also provide
substantial clinical evidence affirming the safety, effectiveness,
efficiency, and reliability of Lunit INSIGHT products.
Since its first publication in 2018, Lunit has advanced the
frontier of medical AI with 55 papers addressing lung abnormalities
- primarily lung nodules - through its Lunit INSIGHT CXR and 45 on
breast cancer with Lunit INSIGHT MMG and Lunit INSIGHT DBT. These
publications have set industry benchmarks and highlighted AI's
potential to stand in for traditional methods of medical image
analysis utilizing AI.
One of Lunit's groundbreaking studies, published in The
Lancet Digital Health, showcased the potential of AI to replace
one human reader in breast cancer screening, a discovery that could
revolutionize current screening practice. The positive results of
this study have led to the real-world implementation at Capio S:t
Göran Hospital in Sweden, where
Lunit INSIGHT MMG has effectively replaced one of the two human
readers typically required for breast cancer screening. This
implementation at Sweden's largest
private hospital is a significant step in addressing Europe's ongoing radiologist shortage and
enhancing the efficiency and accuracy of cancer screening.
Another highlight in the series is a study published in
Radiology. Conducted by Radboud University Medical Center in
The Netherlands, the study
presents a head-to-head validation of multiple commercial AI
products for lung nodule detection on chest radiographs. Lunit
INSIGHT CXR achieved the highest AUC (Area Under the Curve) of
0.93, surpassing human readers and other leading AI vendors. This
exceptional performance underscores Lunit INSIGHT CXR's precision
in identifying lung nodules, further enhancing its clinical
utility, especially in healthcare resource-deprived settings.
"Lunit's rapid publication rate, with 100 papers in just six
years, is more than an academic milestone; it is the foundation of
our mission to conquer cancer through AI. Our research output,
unmatched in the medical AI field, continues to set new standards
and paves the way for advancements," said Brandon Suh, CEO of Lunit. "We have collaborated
with top-tier global institutions, such as the Massachusetts
General Hospital, NHS Trust, and Karolinska
Institute, and have been instrumental in shaping the
understanding and utilization of AI in medical imaging. We are
grateful to our global network of esteemed researchers, clinicians,
and partners who have been integral to our journey."
Lunit's achievement reflects a comprehensive journey, beginning
with the development of an AI-powered solution for lung abnormality
detection and extending through multicenter studies aimed at
improving breast cancer screening protocols. These efforts have
illustrated the practical impact and versatility of AI applications
in various medical settings, including its successful integration
into Europe's double-reading
breast cancer screening systems. Looking to the future, Lunit
remains committed to pioneering further innovations through
research, enhancing patient outcomes, and empowering healthcare
providers with the tools to detect cancer more accurately, quickly,
and effectively, continuously pushing the boundaries of what is
possible.
As of April 2024, Lunit has
reached a total of 125 published papers in SCI journals. This
includes 100 papers on AI medical imaging with the Lunit INSIGHT
suite and an additional 25 papers featuring the Lunit SCOPE suite,
which are AI solutions aimed at precision oncology for optimized
cancer treatment.
About Lunit
Founded in 2013, Lunit is a deep learning-based medical AI
company on a mission to conquer cancer. We are committed to
harnessing AI to ensure accurate diagnosis and optimal treatment
for each cancer patient using AI-powered medical image analytics
and AI biomarkers.
As a medical AI company grounded on clinical evidence, our
findings are presented in major peer-reviewed journals, such as the
Journal of Clinical Oncology and the Lancet Digital Health, and
global conferences, including ASCO and RSNA.
After receiving FDA clearance and the CE Mark, our flagship
Lunit INSIGHT suite is clinically used in approximately 3,000+
hospitals and medical institutions across 40+ countries. Lunit is
headquartered in Seoul, South
Korea, with offices and representatives worldwide. For more
information, please visit lunit.io.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lunit-achieves-historic-milestone-100-peer-reviewed-papers-published-on-its-ai-medical-imaging-suite-302149972.html
SOURCE Lunit